ERBB2 and breast cancer: In the present study, clinicopathological profiles of breast cancer patients revealed that majority of the patients (66%) were at clinical stage T0-T2 (early stage)and with respect to information on steroid hormone receptor status, out of total patients, 176 (58.6%) patients were ER positive, 167 (55.6%) were PgR positive and 163 (54.33%) Her2/nu positive whereas 59 (19.66%) were triple negative status.